Clinical experiment designed to assess clinical efficacy targeting N/A in human patients. Primary outcome: sEV angiogenic capability
This study evaluated the angiogenic capability of serum-derived extracellular vesicles (sEV) from different patient populations including type 2 diabetic subjects, obese individuals with and without diabetes, and subjects with ischemic disease. The research aimed to identify patients who may benefit from autologous sEV administration for pro-angiogenic therapy by comparing sEV properties across these different cardiovascular risk groups. The study involved both in-vitro and in-vivo assessment of angiogenic properties.
sEV isolation from serum, in-vitro and in-vivo angiogenic assays across patient groups
Different angiogenic properties between patient groups, identification of predictive biomarkers
Differential angiogenic capability between patient groups
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.